Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVIL ...